北京天元（杭州）律师事务所 关于思创医惠科技股份有限公司 2025 年第七次临时股东会的法律意见 的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相 应法律责任。 本所及经办律师同意将本法律意见作为本次股东会公告的法定文件，随同其 他公告文件一并提交深圳证券交易所（以下简称"深交所"）予以公告，并依法对 出具的法律意见承担责任。 京天股字（2025）第 797 号 致：思创医惠科技股份有限公司 思创医惠科技股份有限公司（以下简称"公司"）2025 年第七次临时股东会（以 下简称"本次股东会"）采取现场表决与网络投票相结合的方式，现场会议于 2025 年 12 月 29 日（星期一）下午 15:00 在公司会议室（浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室）召开。北京天元（杭州）律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师参加本次股东会现场会议，并根据《中华人民 共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股东会规则》（以下简称"《股东会规则》"）以及《思创医惠科技股份有限 公司章程》（以下简称"《公司章程》"）等有关规 ...

2025 年第七次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300078 证券简称：思创医惠 公告编号：2025-129 思创医惠科技股份有限公司 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025 年 12 月 29 日（星期一）15:00 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 29 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 29 日 9:15 至 15:00 期间的任意时间。 3、现场会议召开地点：浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室 4、会议召开方式：本次股东会采取现场投票表决和网络投票表决相结合的 方式 5、会议召集人：公司董事会 6、会议主持人：公司董事长魏乃绪先生 7、会议召开的合法、合规性：本次股东会的召集、召开及表决程序符合《中 ...

Group 1 - The core viewpoint of the news is that Sichuang Medical's stock performance and financial metrics indicate a mixed outlook, with notable fluctuations in financing activities and shareholder statistics [1][2]. Group 2 - On December 19, Sichuang Medical's stock fell by 1.14%, with a trading volume of 425 million yuan. The financing buy-in amount for the day was 18.70 million yuan, while the financing repayment was 16.07 million yuan, resulting in a net financing buy of 2.63 million yuan. The total financing and securities balance reached 156 million yuan [1]. - The financing balance of Sichuang Medical is 156 million yuan, accounting for 3.21% of the circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high position [1]. - On the same day, Sichuang Medical repaid 1,400 shares in securities lending and sold 13,200 shares, with a selling amount of 57,400 yuan. The remaining securities lending volume was 66,000 shares, with a balance of 287,100 yuan, exceeding the 90th percentile level over the past year, indicating a high position [1]. Group 3 - As of September 30, the number of shareholders for Sichuang Medical was 58,400, a decrease of 11.34% from the previous period. The average circulating shares per person increased by 12.79% to 19,077 shares [2]. - For the period from January to September 2025, Sichuang Medical achieved an operating income of 604 million yuan, representing a year-on-year growth of 6.95%. However, the net profit attributable to the parent company was -4.76 million yuan, showing a year-on-year increase of 98.32% in losses [2]. Group 4 - Since its A-share listing, Sichuang Medical has distributed a total of 532 million yuan in dividends. However, there have been no dividend distributions in the past three years [3].

Core Viewpoint - The recent trend of "small proportion transfer + voting rights arrangement" in A-share control changes has gained momentum, allowing acquirers to gain control of companies at a low cost, exemplified by ST Zhiyun's acquisition for 87 million yuan, despite its market value nearing 2 billion yuan [1][2] Group 1: Transaction Characteristics - Five companies have announced control changes through "small proportion transfer + voting rights arrangement" since November, showcasing a high degree of homogeneity in transaction structure, pricing mechanisms, and the nature of the parties involved [2][4] - The acquisition structures typically involve share transfers between 5% and 10%, which meet regulatory requirements while avoiding triggering mandatory takeover bids, thus facilitating low-cost control [4][7] - The pricing mechanism predominantly features discounted transactions, with ST Zhiyun and others selling shares below the market price prior to announcements, reducing financial pressure on acquirers [5][6] Group 2: Financial and Operational Context - The companies involved generally have small to medium market capitalizations, with four out of five having market values between 2 billion and 5 billion yuan, and they face performance pressures, indicating a low risk of delisting [8][9] - Financial data reveals that most companies are underperforming, with four reporting losses in the first three quarters of the year, while only one, Hualan Group, has turned a profit [9][10] Group 3: Stakeholder Dynamics - The acquirers are predominantly private entities, which allows for quicker decision-making processes compared to state-owned enterprises, enhancing transaction efficiency [7][11] - The original shareholders often retain a portion of their stakes, creating a shared interest in the company's future performance, which aligns the interests of both parties [17] Group 4: Regulatory and Market Environment - The emergence of this acquisition model is supported by regulatory changes that encourage market-oriented mergers and acquisitions, particularly for private capital [18][19] - Recent regulatory proposals have raised concerns about the compliance of voting rights arrangements, which could impact future control transactions if enacted [22]

北京商报讯（记者 丁宁）12月19日晚间，深交所官网显示，深交所向思创医惠（300078）下发监管 函。 据悉，2017年6月，章笠中作为公司时任董事长兼总经理，以公司子公司医惠科技有限公司（以下简 称"医惠科技"）名义为其个人7600万元借款提供担保。章笠中未将上述担保事项告知公司，导致公司未 履行相应的审议程序，未及时披露有关事项。 此外，2024年11月，因章笠中违约，债权人提起诉讼并向法院申请财产保全，医惠科技的募集资金专项 账户被冻结资金5766.25万元。2025 年5月，章笠中履行还款义务后，法院裁定解除对医惠科技5766.25 万元银行存款的冻结。 深交所表示，思创医惠未严格管控上市公司及子公司公章，未能有效防范违规担保事项发生，公司印章 管理内部控制存在缺陷。公司的上述行为违反了《创业板股票上市规则》第1.4条和《创业板上市公司 规范运作指引》第1.4条、第8.1.1条、第8.1.7条的规定。要求公司董事会充分重视上述问题，吸取教 训，及时整改，杜绝上述问题的再次发生。 同时，鉴于上述违规事实及情节，深交所对思创医惠时任董事长兼总经理章笠中给予通报批评的处分。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 出品：新浪财经上市公司研究院 文/夏虫工作室 核心观点：在思创医惠（维权）控股权交易中，其高管总经理魏乃绪通过"协议转让+表决权"模式实现 MBO收购。思创医惠曾一度卖身国资，但由于不符合国资相关要求被终止。值得注意的是，思创医惠 MBO式控股背后闪现国资身影。 随着二级市场行情火爆，A股上市公司控制权交易也显得异常活跃。据wind统计，截止12月15日，出现 实控人变更的上市公司数量超170家，从变更方式看分别包括协议转让、表决权委托、无偿划转、司法 拍卖等几种形式。 | A 正存代码 | 比芬名材 | 止存争 | A | V 事件大学 | 量量 RA | | 发生日期Y | 盘体损失 | V | 拔露日期。 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 300551. SZ | 古盈科技 | 股票 | | 公司资料变 | 实际控制人 | দ | 2025-12-12 | 实际控制 | A | 2025-12-15 | | 603179. SH | 新泉股份 | ...

Group 1 - The company Shichuang Medical (SZ 300078) faced regulatory action due to its former chairman and general manager, Zhang Lizhong, providing a personal loan guarantee of 76 million RMB without proper disclosure, violating multiple regulations [1] - As a result of Zhang's actions, a lawsuit was filed by creditors in November 2024, leading to the freezing of 57.6625 million RMB in a special fundraising account for a subsidiary [1] - The company reported its revenue composition for the first half of 2025, with real estate sales accounting for 53.84%, business intelligence for 39.28%, and smart healthcare for 6.87% [2] Group 2 - As of the latest report, Shichuang Medical has a market capitalization of 4.9 billion RMB [3]

Core Viewpoint - The DRG/DIP concept sector experienced a significant increase of 3.87%, leading the market in terms of growth, with notable performances from stocks such as Jiahe Meikang and Saily Medical, which reached their daily limit up [1][2]. Group 1: Market Performance - The DRG/DIP concept sector had 19 stocks rising, with Jiahe Meikang hitting a 20% limit up, followed by Saily Medical at limit up, and other notable gainers including Weining Health, Dian Diagnostics, and Sichuang Medical, which rose by 11.11%, 8.65%, and 5.77% respectively [1]. - The sector saw a net inflow of 737 million yuan from main funds, with 17 stocks receiving net inflows, and 11 stocks exceeding 10 million yuan in net inflow [2]. - The top net inflow stock was Weining Health, attracting 347 million yuan, followed by Saily Medical, Rongke Technology, and Jiayuan Technology with net inflows of 166 million yuan, 83.78 million yuan, and 44.88 million yuan respectively [2]. Group 2: Fund Flow Ratios - Saily Medical, Digital Certification, and Weining Health had the highest net inflow ratios, with rates of 29.65%, 13.45%, and 12.89% respectively [3]. - The top stocks in the DRG/DIP concept based on net inflow include Weining Health with a daily increase of 11.11% and a turnover rate of 15.28%, and Saily Medical with a 9.99% increase and a turnover rate of 12.43% [3][4]. - Other notable stocks include Rongke Technology, Jiayuan Technology, and Jiahe Meikang, which also showed positive performance with increases of 0.90%, 3.27%, and 20.01% respectively [4].

一、基本情况概述 思创医惠科技股份有限公司（以下简称"公司""本公司"）第一大股东路 楠先生与公司董事兼总经理魏乃绪先生控制的企业苍南芯盛企业管理合伙企业 （有限合伙）（以下简称"苍南芯盛"）于 2025 年 11 月 15 日签署了《股份转 让协议》，约定路楠先生拟通过协议转让的方式将其所直接持有的本公司共计 62,739,500 股的股份（占公司总股本的 5.61%）转让给苍南芯盛（以下简称"本 次股份转让"）。同日，公司股东苍南县思加物联智能合伙企业（有限合伙）（以 下简称"思加物联"）与苍南芯盛及其实际控制人魏乃绪先生共同签署了《表决 权委托协议》，约定在协议有效期内，思加物联不可撤销地将持有的本公司 63,890,185 股（占总股本 5.72%）股份以及上述股份因配股、送股、转增股本等 而增加的股份对应的表决权、召集权、提名和提案权、参会权等相关权利委托给 苍南芯盛行使（以下简称"本次表决权委托"）。本次表决权委托的期限为 36 个月，自公司股东会审议通过本次表决权委托相关事项之日起生效。 苍南芯盛与苍南芯创企业管理合伙企业（有限合伙）（以下简称"苍南芯创"） 同为魏乃绪先生控制的企业，苍南芯创持 ...

从资金流向上来看，当日AI医疗板块主力资金净流出8252.25万元，游资资金净流出8136.03万元，散户 资金净流入1.64亿元。AI医疗板块个股资金流向见下表： 证券之星消息，12月16日AI医疗板块较上一交易日下跌0.98%，思创医惠领跌。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。AI医疗板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...